Does IL-17i Exposure Increase IBD Risk in Psoriasis Patients?

Exposure to interleukin-17 inhibitors (IL-17is) does not increase the risk of inflammatory bowel disease (IBD) among patients with psoriasis, according to the results of a recent study.

The researchers conducted a retrospective cohort analysis of patients with psoriasis with and without exposure to IL-17is, with primary outcomes including 6-month and 1-year IBD incidence.

Overall, the crude 6-month IBD incidence was 0.16% among patients with psoriasis with a history of exposure to any IL-17i, 0.24% among those with secukinumab exposure alone, and 0.11% among those who were unexposed to IL-17is.

Crude 1-year IBD incidence was 0.27% among those with IL-17i exposure, 0.32% in those with secukinumab exposure alone, and 0.19% among those unexposed to IL-17is.

No significant difference was observed in the odds of developing IBD at 6 months or at 1 year.

“Incidence of IBD among psoriasis patients exposed to IL-17i is low and the risk appears similar to unexposed psoriasis patients,” the researchers concluded.

—Michael Potts

Reference:
Wright S, Alloo A, Strunk A, Garg A. Real-world risk of new onset inflammatory bowel disease among psoriasis patients exposed to interleukin 17 inhibitors [published online April 11, 2020]. J Am Acad Dermatol. doi: 10.1016/j.jaad.2020.04.010